

COVID-19 Vaccination Quick Links

Current as of December 14, 2022

Numerous tools and resources are available to inform the COVID-19 vaccination efforts of healthcare providers, including ASPR TRACIE's [technical assistance response](#) focused on the healthcare facility response during the first six months of the vaccine roll out. ASPR TRACIE created this list to assist clinicians in quickly finding the most relevant and current information about COVID-19 vaccines available in the United States, their intended populations, recommendations for their use, effectiveness and safety issues, potential adverse events to be aware of, the effects of SARS-CoV-2 variants, and resources to help communicate with patients. Additional resources are also listed to access more detailed information.

Vaccines Available in the U.S.

[Pfizer-BioNTech](#) (Comirnaty)

FDA approved—monovalent

- 2 dose primary series in individuals 12 years of age & older

FDA Emergency Use Authorization (EUA) - monovalent

- First 2 doses of 3 dose primary series in individuals 6 months to 4 years of age
- 2 dose primary series in individuals 5 years of age & older
- 3rd dose in primary series for certain immunocompromised individuals 5 years of age & older

FDA EUA—bivalent

- Booster dose in individuals 5 years of age & older at least 2 months after completion of primary series or booster with monovalent vaccine
- Third dose of 3 dose primary series in individuals 6 months to 4 years of age

[Novavax](#)

FDA EUA

- 2 dose primary series in individuals 12 years of age & older
- Booster dose in individuals 12 years of age & older at least 6 months after primary series

[Moderna](#) (Spikevax)

FDA approved—monovalent

- 2 dose primary series in individuals 18 years of age & older

FDA EUA—monovalent

- 2 dose primary series in individuals 6 months & older
- 3rd dose in primary series for certain immunocompromised individuals 6 months of age & older

FDA EUA—bivalent

- Booster dose in individuals 6 months of age & older at least 2 months after completion of primary series or booster with monovalent vaccine

[Johnson & Johnson/Janssen](#)








FDA EUA*

- 1 dose in individuals 18 years of age & older
- 2nd dose in primary series for certain immunocompromised individuals 18 years of age & older
- Booster dose at least 2 months after primary dose for those ages 18 and older, including those who are moderately or severely immunocompromised

*CDC [preferentially recommends](#) use of Pfizer-BioNTech, Moderna, or Novavax vaccines due to the rare but noted risk of thrombosis with thrombocytopenia syndrome associated with the Johnson & Johnson/Janssen vaccine. The FDA [limits](#) authorized use of the Johnson & Johnson/Janssen vaccine to those 18 years of age and older for whom other authorized/approved vaccines are not clinically appropriate or accessible or would not otherwise receive a COVID-19 vaccine.

The [recommended timing](#) of the 2nd dose for those who received a Pfizer-BioNTech, Moderna, or Novavax vaccine for their primary series is dependent upon age, sex, risk of severe disease, rates of community transmission, and immunocompromised status.

FDA [authorized](#) heterologous, or mix-and-match, booster doses using any vaccine authorized as a booster. The timing of the booster dose and eligible population are based on the vaccine used for the primary series.

 Recommendations	
Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Recommendations CDC Interim Clinical Considerations for Use of COVID-19 Vaccines in the US	
 SARS-CoV-2 Variants Variants of the Virus  Effectiveness COVID-19 Vaccine Effectiveness  Safety Ensuring COVID-19 Vaccine Safety in the U.S.	 Potential Adverse Events Common Side Effects Anaphylaxis Guillain-Barre Syndrome Myocarditis/Pericarditis Thrombosis with Thrombocytopenia Syndrome
 Communicating with Patients	
Be a COVID-19 Vaccine Champion Webinar Building Confidence in COVID-19 Vaccines Communication Resources for COVID-19 Vaccines COVID-19 Vaccine Education	COVID-19 Vaccine for Children Immunization Communications Resource Toolkit Vaccine Communications Tips Vaccine Recipient Education
 Additional Resources	
ASPR TRACIE: COVID-19 Vaccine Resources Collection CDC: Vaccines for COVID-19	FDA: COVID-19 Vaccines NIH: COVID-19 Vaccines